PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ANTIDEPRESSIVE AGENTS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources

Haemodynamic effects of pirlindole, a new tetracyclic antidepressant agent.

Cardiovascular dynamic, inotropic and electrophysiologic effects of the new tetracyclic antidepressant 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]-carbazole hydrochloride (pirlindole) (0.5, 1, 2.5, 5 and 10 mg/kg, i.v.) were investigated in anaesthetized dogs and compared with those of i.v. imipramine (0.5, 1, 2.5 and 5 mg/kg) administration. Noradrenaline (norepinephrine)-induced systemic blood pressure increase was significantly potentiated by imipramine but not by pirlindole. Severe hypotension was caused by most imipramine doses, whereas the initial blood pressure fall after pirlindole was followed by an increase. Heart rate did not alter with lower prilindole doses but increased after 2.5 mg/kg. Imipramine caused severe tachycardia. Pirlindole had no effects on contractility but imipramine was negative-inotropic. Left ventricular end-diastolic pressure fell after pirlindole; imipramine caused transient decrease in filling pressure between 0.5 and 2.5 mg/kg, whereas 5 mg/kg significantly elevated this variable. Myocardial oxygen consumption increased with 5 and 10 mg/kg pirlindole but was reduced by imipramine. Pirlindole did not induce changes in the electrophysiology of the heart. Imipramine decreased PQ-time and elevated ST-T segments indicating myocardial ischaemia. Imipramine effects on electrical conduction were deleterious so that no dog survived 10 mg/kg. These results suggest that pirlindole may be a possible therapeutic regimen for treatment of depressed human patients with a previous history of cardiovascular disease.

Animals↗

The action of trelibet, a new antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery.

Trelibet, a new antidepressant, used at 10(-7)-10(-4) M failed to affect the [3H]noradrenaline ([3H]NA) release evoked from the isolated main pulmonary artery of the rabbit low frequency (2 Hz) nerve stimulation whether the neuronal uptake inhibitor cocaine (3 X 10(-5) M) was present or not. Its metabolite (EGYT-2760) however, potentiated the nerve-evoked release of [3H]NA. In the absence of cocaine both the resting and the stimulation-evoked release of 3H increased in response to EGYT-2760. These effect were accompanied by muscle contraction. The EGYT-2760-potentiated transmitter release was inhibited either by exogenously applied 1-noradrenaline (10(-6) M) or clonidine (10(-6) M), preferential agonists of presynaptic alpha 2-adrenoceptors. The 1-noradrenaline-induced inhibition of transmitter release potentiated by EGYT-2760 was antagonized by 3 X 10(-7) M yohimbine, a preferential alpha 2-adrenoceptor inhibitor. In the absence of cocaine, Ca2+ removal from the external medium failed to affect the 3H outflow-increasing effect of EGYT-2760 but abolished the nerve-evoked release-potentiating action of this compound. It is concluded that the metabolite of trelibet exerts a 'yohimbine-like' action, as well as a 'tyramine-like' effect in peripheral sympathetic nerve fibres.

Animals↗

Azetidine derivatives of tricyclic antidepressant agents.

Tricyclic derivatives of azetidine were synthesized and screened for their potential antidepressant activity. The active series had the tricyclic ring attached to position 1 and a basic group in position 3 of the azetidine. The most interesting compounds were comparable to the reference standards for reserpine antagonism in mice, the most active being the dextrorotatory methylamino derivative 84. The pharmacological profile classifies it as a CNS stimulant devoid of peripheral anticholinergic activity.

Animals↗

[Do antidepressive agents have analgesic effects?].

Patients with chronic pain are often depressed, and antidepressants have been widely used in the treatment of these patients. Well controlled clinical studies have shown that antidepressants have analgesic effects, apparently independent of changes in mood, and in lower doses than used in the treatment of depression. Good results have been reported for several types of chronic pain, especially headache and facial pain, arthritis, fibromyalgia and neuralgias. In addition, antidepressants have also an indirect analgesic action by relieving a depressive condition associated with chronic pain.

Analgesics↗